Children's Vaccine Initiative : Achieving the Vision.
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , |
| Format: | Electronic eBook |
| Language: | English |
| Published: |
Washington :
National Academies Press,
1900.
|
| Subjects: | |
| Online Access: | Full text (Emerson users only) Full text (Emmanuel users only) Full text (NECO users only) Full text (MCPHS users only) Full text (Wentworth users only) |
Table of Contents:
- ""The Children's Vaccine Initiative""; ""Copyright""; ""Preface""; ""Acknowledgments""; ""Contents""; ""1 Executive Summary""; ""THE CHILDREN'S VACCINE INITIATIVE""; ""THE INSTITUTE OF MEDICINE REPORT""; ""COMMITTEE FINDINGS""; ""Resources and Infrastructure""; ""Vaccine Demand and Supply""; ""Demand""; ""Supply""; ""Innovation""; ""Investing in New and Improved Vaccines""; ""Stages of Vaccine Development""; ""Pilot Production""; ""Clinical Trials""; ""Scaleup and Large-Scale Manufacture""; ""Technology Transfer""; ""A STRATEGY TO ENHANCE U.S. PARTICIPATION""; ""NOTE""; ""REFERENCE""
- ""2 Why a Children's Vaccine Initiative?""""PROGRESS TOWARD UNIVERSAL CHILDHOOD IMMUNIZATION""; ""Limits of the Expanded Program on Immunization""; ""THE CHILDREN'S VACCINE INITIATIVE""; ""Characteristics of CVI Vaccines""; ""Vaccines Should Be Single Dose""; ""Vaccines Should Be Administered Near Birth""; ""Vaccines Should Be Combined in Novel Ways""; ""Vaccines Should Be Heat Stable""; ""Vaccines Should Be Effective Against Additional Diseases""; ""Vaccines Should Be Affordable""; ""Concerns About the CVI""; ""RELEVANCE OF THE CVI TO U.S. IMMUNIZATION EFFORTS""
- ""Status of Immunization Efforts in the United States""""A Role for the CVI in the United States""; ""REFERENCES""; ""3 Resources and Infrastructure""; ""RESOURCES IN THE UNITED STATES""; ""U.S. Federal Agencies and Programs""; ""U.S. Agency for International Development""; ""Center for Biologics Evaluation and Research, U.S. Food and Drug Administration""; ""Centers for Disease Control and Prevention""; ""U.S. Department of Defense""; ""National Institutes of Health""; ""National Vaccine Program""; ""Other Federal Programs""; ""U.S. State Vaccine Manufacturers""; ""Massachusetts""
- ""Michigan""""U.S.-Based Pharmaceutical Firms""; ""Connaught Laboratories, Inc.""; ""Lederle-Proxis Biologicals""; ""Merck & Co., Inc.""; ""SmithKline Beecham""; ""Wyeth-Ayerst""; ""Development-Stage Companies""; ""North American Vaccine""; ""MedImmune""; ""Univax Biologics, Inc.""; ""Nongovernmental Organizations""; ""The Children's Defense Fund""; ""March of Dimes Birth Defects Foundation""; ""Rockefeller Foundation""; ""Rotary Foundation""; ""INTERNATIONAL RESOURCES""; ""Multilateral Organizations""; ""Pan American Health Organization""; ""PAHO Revolving Fund""; ""SIREVA Project""
- ""United Nations Development Program""""United Nations Children's Fund""; ""Vaccine Independence Initiative""; ""World Bank""; ""World Health Organization""; ""Expanded Program on Immunization""; ""Program for Vaccine Development""; ""Children's Vaccine Initiative""; ""Public-Sector Resources""; ""Private-Sector Resources""; ""Nongovernmental Organizations""; ""Task Force for Child Survival and Development""; ""Save the Children Fund""; ""REFERENCES""; ""4 Vaccine Demand and Supply""; ""GLOBAL DEMAND AND SUPPLY""; ""Demand""; ""Regional Demand""; ""Supply""; ""Procurement""; ""Innovation""